Endometrial Carcinoma – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of endometrial carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of endometrial carcinoma for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

Clarivate Epidemiology’s endometrial carcinoma forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with endometrial carcinoma each year?
• In developing countries, what impact will economic growth and development have on the number of people diagnosed with endometrial carcinoma each year?
• How will the declining risk of recurrence change the number of people diagnosed with endometrial carcinoma each year?
• Of all people diagnosed with endometrial carcinoma, how many in each country are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of endometrial carcinoma over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

In total, Clarivate Epidemiology forecasts 25 endometrial carcinoma patient populations; they include the following:

• Diagnosed incident cases of endometrial carcinoma.
• Diagnosed incident cases of stage I endometrial carcinoma.
• Diagnosed incident cases of stage I low- and intermediate-risk endometrial carcinoma.
• Diagnosed incident cases of stage I high-risk endometrial carcinoma.
• Diagnosed incident cases of stage II endometrial carcinoma.
• Diagnosed incident cases of stage III endometrial carcinoma.
• Diagnosed incident cases of stage IV endometrial carcinoma.
• Diagnosed incident cases of recurrent early-stage low- and intermediate-risk endometrial carcinoma.
• Diagnosed incident cases of recurrent early-stage high-risk endometrial carcinoma.
• Diagnosed incident cases of recurrent early stage II endometrial carcinoma.
• Diagnosed prevalent cases of early-stage endometrial cancer.
• Diagnosed prevalent cases of advanced-stage drug-treatable endometrial cancer.
• Diagnosed prevalent cases of endometrial cancer.
• Diagnosed cases of drug-treatable early-stage first-line endometrial cancer.
• Diagnosed cases of drug-treatable advanced first-line endometrial cancer.
• Diagnosed cases of drug-treatable advanced second-line endometrial cancer.
• Diagnosed cases of drug-treatable advanced third-line endometrial cancer drug-treatable population.
• … and more (details available on request).

Note: Coverage may vary by country.